Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8088-8096

  Dong, Ying ^a,b   Bey, Erik A ^a,b   Li, Long Shan ^a,b   Kabbani, Wareef ^b   Yan, Jingsheng ^a   Xie, Xian Jin ^a   Hsieh, Jer Tsong ^a   Gao, Jinming ^a   Boothman, David A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARQ 501; BETA LAPACHONE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL DEATH; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IONIZING RADIATION; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL DEATH; COLONY-FORMING UNITS ASSAY; COMET ASSAY; DICUMAROL; DNA DAMAGE; DNA, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; NAPHTHOQUINONES; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; REGRESSION ANALYSIS;

EID: 78049311247     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1418     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Niciforovic A, Djordjevic J, Adzic M, Vucic V, Mitrasinovic PM, Radojcic MB. Experimental and systems biology studies of the molecular basis for the radioresistance of prostate carcinoma cells. Ann Biomed Eng 2008;36:831-8.
3. Buron C, Le Vu B, Cosset JM, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys 2007;67:812-22. (Pubitemid 46215887)
4. van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006;64:534-43.
5. Planchon S, Pink J, Tagliarino C, Bornmann W, Varnes M, Boothman D. β-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp Cell Res 2001;267:95-106. (Pubitemid 32579145)
6. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 2006;281:33684-96.
7. Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone. Cancer Res 2007;67:6936-45. (Pubitemid 47105541)
8. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in β-lapachone-mediated cell death. J Biol Chem 2001;276:19150-9.
9. Tagliarino C, Pink J, Reinicke K, Simmers S, Wuerzberger-Davis S, Boothman D. Mu-calpain activation in β-lapachone-mediated apoptosis. Cancer Biol Ther 2003;2:141-52.
10. Bentle M, Bey E, Dong Y, Reinicke K, Boothman D. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol 2006;37:203-18. (Pubitemid 44795624)
11. Reinicke K, Bey E, Bentle M, et al. Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H: quinone oxidoreductase 1 levels. Clin Cancer Res 2005;11:3055-64. (Pubitemid 40525212)
12. Bey EA, Wuerzberger-Davis SM, Pink JJ, et al. Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. J Cell Physiol 2006;209:604-10.
13. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009;12:153-6.
14. Peralta-Leal A, Rodriguez MI, Oliver FJ. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol 2008;10:318-23.
15. Drew Y, Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol ;22:67-71.
16. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
17. Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008;27:1368-77. (Pubitemid 351655175)
18. Noël G, Giocanti N, Fernet M, Mégnin-Chanet F, Favaudon V. Poly (ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol 2003;4:7. (Pubitemid 38597763)
19. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res 2008;18:27-47.
20. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: "PAR-laying" NAD+ into a nuclear signal. Genes Dev 2005;19:1951-67.
21. Bey EA, Bentle MS, Reinicke KE, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proc Natl Acad Sci U S A 2007;104:11832-7.
22. Boothman DA, Schlegel R, Pardee AB. Anticarcinogenic potential of DNA-repair modulators. Mutat Res 1988;202:393-411.
23. Boothman D, Pardee A. Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc Natl Acad Sci U S A 1989;86:4963-7. (Pubitemid 19182215)
24. Hermisson M, Wagenknecht B, Wolburg H, Glaser T, Dichgans J, Weller M. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. Oncogene 2000;19:2338-45. (Pubitemid 30307210)
25. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000;275:5416-24. (Pubitemid 30115173)
26. Lee YJ, Galoforo SS, Berns CM, et al. Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem 1998;273:5294-9.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
28. Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 2007;17:461-80. (Pubitemid 46699662)
29. Machado SG, Robinson GA. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat Med 1994;13:2289-309.
30. Min W, Wang ZQ. Poly(ADP-ribose) glycohydrolase (PARG) and its therapeutic potential. Front Biosci 2009;14:1619-26.
31. Boothman DA, Greer S, Pardee AB. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 1987;47:5361-6.
32. Wuerzberger SM, Pink JJ, Planchon SM, Byers KL, Bornmann WG, Boothman DA. Induction of apoptosis in MCF-7: WS8 breast cancer cells by β-lapachone. Cancer Res 1998;58:1876-85.
33. Gerweck LE, Vijayappa S, Kurimasa A, Ogawa K, Chen DJ. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res 2006;66:8352-5. (Pubitemid 44449143)
34. Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 2010;7:44-54.
35. Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol) 2010;22:157-72.
36. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009;8:387-92.
37. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC, Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73:1043-8.
38. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67. (Pubitemid 38180960)
39. Sakamoto-Hojo ET, Balajee AS. Targeting poly(ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Anticancer Agents Med Chem 2008;8:402-16.
40. Greco WR, Park HS, Rustum YM. Application of a new approach for the quantitation of drug synergism to the combination of cis- diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 1990;50:5318-27.
41. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
42. Suzuki M, Amano M, Choi J, et al. Synergistic effects of fradiation and β-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 2006;165:525-31.
43. Dong Y, Chin SF, Blanco E, et al. Intratumoral delivery of β-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009;15:131-9.
44. Blanco E, Bey EA, Khemtong C, et al. β-Lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 2010;70:3896-904.